Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Christopher Tor Sauter, MD, Luca L Bernabei, BA, Adam Waxman, MD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Dan T. Vogl, MD, Sara Whittington,, RN, MPH, Colleen Harker Erb, CRNP, Patricia Mangan, CRNP, Mary Sanchez, CRNP, Edward A. Stadtmauer, MD FACP

Blood (2019) 134 (Supplement_1): 5598.

https://doi.org/10.1182/blood-2019-132087

Published: 2019

Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2019) 134 (Supplement_1): 2642.

https://doi.org/10.1182/blood-2019-129137

Published: 2019

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Family Studies of Whim Syndrome

David C. Dale, MD, Emily Dick, BA, Merideth L. Kelley, MSc, Vahagn Makaryan, MD, Jim Connelly, MD, Audrey Anna Bolyard, RN, BS

Blood (2019) 134 (Supplement_1): 215.

https://doi.org/10.1182/blood-2019-126234

Published: 2019

Journal Articles

Mucormycosis Among Children with Hematological Malignancies Is Associated with High-Risk Acute Lymphoblastic Leukemia and Is Often Salvageable

Sarah Elitzur, MD, Shlomit Barzilai, MD, Assaf Arie Barg, MD, Bella Bielorai, MD, Ronit Elhasid, MD, Salvador Fischer, MD, Yariv Fruchtman, MD, Gil Gilad, MD, Shai Izraeli, MD, Mira Kharit, MD, Ruth Laor, MD, Itzhak Levy, MD, Ronit Nirel, PhD, Dror Raviv, MD, Yael Shachor-Meyouhas, MD, Isaac Yaniv, MD, Nira Arad-Cohen, MD

Blood (2018) 132 (Supplement 1): 3964.

https://doi.org/10.1182/blood-2018-99-113072

Published: 2018

Journal Articles

Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study

John C. Byrd, MD, Jennifer A. Woyach, MD, Richard R. Furman, MD, Peter Martin, FRCPC, MD MS, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Deborah M. Stephens, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, John M. Pagel, MD PhD, Dih-Yih Chen, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, Nitin Jain, MD, William G. Wierda, MD PhD

Blood (2018) 132 (Supplement 1): 692.

https://doi.org/10.1182/blood-2018-99-110451

Published: 2018

Journal Articles

Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome

Joseph Maakaron, MD, Sam Penza, MD, Zeinab El Boghdadly, MBBCh, Caron A. Jacobson, MD, Bradley Hunter, MD MPH, Matthew J. Frigault, MD, Jeremy S. Abramson, MD MMSc, Justin Kline, MD, Jonathon B. Cohen, MD MS, Ajay K. Gopal, MD, Utkarsh H. Acharya, DO, Samantha Jaglowski, MD MPH, Philippe Armand, MD PhD

Blood (2018) 132 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2018-99-120065

Published: 2018

Journal Articles

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Jia Ruan, Peter Martin, Paul Christos, Leandro Cerchietti, Wayne Tam, Bijal Shah, Stephen J. Schuster, Amelyn Rodriguez, David Hyman, Maria Nieves Calvo-Vidal, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, Morton Coleman, John P. Leonard

Blood (2018) 132 (19): 2016–2025.

https://doi.org/10.1182/blood-2018-07-859769

Published: 2018

Journal Articles

Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes

Narjust Duma, MD, Jonas Paludo, MD, Brian Kabat, B.S., Aaron Tande, MD, Kari G Chaffee, MS, Timothy G. Call, MD, Saad Sirop Kenderian, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Melissa C. Larson, M.S., Asher A. Chanan-Khan, MD, Michael Conte, PA-C, Susan Marie Schwager, Susan L Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2017) 130 (Supplement 1): 4327.

https://doi.org/10.1182/blood.V130.Suppl_1.4327.4327

Published: 2017

Journal Articles

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi, Stéphanie Poulain, MD, Lise Willems, MD, Fatiha Merabet, Charles Herbaux, Damien Roos-Weil, Alix Baugier de Materre, Xavier Roussel, Sabine Tricot, Jehan Dupuis, MD, Ronan Le Calloch, Benoit Bareau, Marie C Bene, PharmD,DPhil, Veronique Leblond

Blood (2017) 130 (Supplement 1): 4046.

https://doi.org/10.1182/blood.V130.Suppl_1.4046.4046

Published: 2017

Journal Articles

Systematic Review of Infectious Events in Prospective Trials of Ibrutinib

Benjamin Tillman, MD, James Michael Pauff, MD PhD, Gowri Satyanarayana, MD, Mahsa Sharifi Talbott, PharmD, Jeremy Warner, MD MS

Blood (2017) 130 (Supplement 1): 3460.

https://doi.org/10.1182/blood.V130.Suppl_1.3460.3460

Published: 2017

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, MD PhD, Peter Martin, FRCPC, MD MS, Paul J Christos, Dr.P.H., M.S., Leandro Cerchietti, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Wayne Tam, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, David Hyman, Maria Nieves Calvo Vidal, PhD, Lidia Roman Gonzalez, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2017) 130 (Supplement 1): 154.

https://doi.org/10.1182/blood.V130.Suppl_1.154.154

Published: 2017

Journal Articles

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Sharmilan Thanendrarajan, MD, Jerry Puryear, PharmD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Pankaj Mathur, MD, Meera Mohan, MD, Sandra Susanibar, MD, Jorge Jo Kamimoto, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Leo Rasche, MD, Niels Weinhold, PhD, Brian A Walker, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 1858.

https://doi.org/10.1182/blood.V130.Suppl_1.1858.1858

Published: 2017

Journal Articles

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Farrukh T. Awan, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Sharon Waymer, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 4386.

https://doi.org/10.1182/blood.V128.22.4386.4386

Published: 2016

Journal Articles

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Ying Huang, MA, MS, Beth A Christian, MD, Don M Benson, MD PhD, Jeffrey Jones, MD MPH, Christopher Flowers, MD MS, Leonard T. Heffner, MD, Cynthia Jenkins, RN, Jennfer Sexton, MHA, CCRC, Alison Neal, MPH, Melissa Kives, MPH, Kristie A. Blum, MD

Blood (2016) 128 (22): 1776.

https://doi.org/10.1182/blood.V128.22.1776.1776

Published: 2016

Journal Articles

Impact of Previous Invasive Fungal Infections on the Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cells

Gaetano Maffongelli, Sr., PhD, Gaetano Maffongelli, Sr., PhD, Gaetano Maffongelli, Sr., PhD, Laura Cudillo, MD, Fabio Di Piazza, MSc, Vincenzo Malagnino, Giovanna de Santis, Benedetta Mariotti, Eleonora Ceresoli, Raffaella Cerretti, MD, Alessandra Picardi, MD, Massimo Andreoni, William Arcese, MD, Loredana Sarmati

Blood (2016) 128 (22): 5748.

https://doi.org/10.1182/blood.V128.22.5748.5748

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 622.

https://doi.org/10.1182/blood.V128.22.622.622

Published: 2016

Journal Articles

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Jatin J. Shah, MD, Lei Feng, MS, Donna Weber, MD, Sheeba K Thomas, MD, Michael Wang, MD, Francesco Turturro, MD, Muzaffar H. Qazilbash, MD, Nina Shah, MD, Qaiser Bashir, MD, Uday R. Popat, MD, Elisabet E. Manasanch, MD, Silvia C Munoz, RN, Ashley Landry, RN, Kathleen Mendoza, RN, Yago Nieto, MD PhD, Richard E. Champlin, MD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 3155.

https://doi.org/10.1182/blood.V126.23.3155.3155

Published: 2015

Journal Articles

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, MD, Lei Feng, MS, Sheeba K. Thomas, MD, Donna Weber, MD, Michael Wang, MD, Elisabet E. Manasanch, MD, Kathleen Mendoza, RN, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 376.

https://doi.org/10.1182/blood.V126.23.376.376

Published: 2015

Journal Articles

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Jatin J. Shah, MD, Lei Feng, MS, Elisabet E. Manasanch, MD, Donna Weber, MD, Sheeba K Thomas, MD, Francesco Turturro, MD, Nina Shah, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Qaiser Bashir, MD, Silvia C Munoz, RN, Ashley Landry, RN, Kathleen Mendoza, RN, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 187.

https://doi.org/10.1182/blood.V126.23.187.187

Published: 2015

NARROW

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Infectious Complications Associated with CAR T-Cell Therapy

Family Studies of Whim Syndrome

Mucormycosis Among Children with Hematological Malignancies Is Associated with High-Risk Acute Lymphoblastic Leukemia and Is Often Salvageable

Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study

Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Systematic Review of Infectious Events in Prospective Trials of Ibrutinib

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Impact of Previous Invasive Fungal Infections on the Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cells

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only